Workflow
诺和诺德推进减肥药Amycretin临床试验

Group 1 - Novo Nordisk is advancing clinical trials for the weight management drug Amycretin, which targets GLP-1 for diabetes and weight loss, through both subcutaneous injection and oral administration [1] - Amycretin is entering Phase 3 development specifically for weight management purposes [2] Group 2 - Altimmune's stock increased by 10.9%, while Novo Nordisk's ADR rose over 2.2%. Other pharmaceutical companies such as Roche, AstraZeneca, and Pfizer also saw stock increases of at least 1.2% [2] - Novo Nordisk's stock price is reported at $80.49, with an increase of $1.76 (+2.24%), and a market capitalization of approximately $357.3 billion [3] - Roche's stock price is $41.90, with an increase of $0.81 (+1.97%), and a market capitalization of approximately $36.15 billion [3] - AstraZeneca's stock price is $75.13, with an increase of $1.39 (+1.89%), and a market capitalization of approximately $233 billion [3]